Ratings Streamline Health Solutions, Inc.

Equities

Delayed Nasdaq Other stock markets 10:50:05 2024-04-25 am EDT			5-day change	1st Jan Change
0.328 ^USD	-3.53%		-1.20%	-22.82%

Feb. 07	Streamline Health Solutions, Inc. Appoints New Directors	CI
Feb. 07	Streamline Health Solutions, Inc. announced that it has received $4.4 million in funding	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
STREAMLINE HEALTH SOLUTIONS, INC.	-22.82%	19.33M		-
CVS HEALTH CORPORATION	-15.03%	85.42B		B-
HCA HEALTHCARE, INC.	+15.76%	84.38B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.39B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-13.30%	17.49B		B
FRESENIUS SE & CO. KGAA	-2.92%	16.44B		A-
QUEST DIAGNOSTICS INCORPORATED	-1.89%	15.28B		A-
FRESENIUS MEDICAL CARE AG	-0.32%	12.22B		A-
PURE HEALTH HOLDING	-31.23%	11.98B	-	-
EUROFINS SCIENTIFIC SE	-2.48%	11.71B		A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality